rase activity exhibit resistance to imatinib. Leuk Lymphom. 2008, 49:1168 77. 35. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005, 435:834 8. 36. Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic WZ3146 EGFR inhibitor Hodgkin lymphoma. Blood. 2008, 111:2825 32. 37. Woods K, Thompson JM, Hammond SM. Direct regulation of an oncogenic micro RNA cluster by E2F transcription factors. J Biol Chem. 2007, 282:2130 4. 38. Cimmino A, Calin GA, Fabbri M, et al. miR 15 and miR 16 induce apoptosis by targeting Bcl 2. Proc Natl Acad Sci USA. 2005, 102:13944 9. 39. Xia L, Zhang D, Du R, et al. miR 15b and miR 16 modulate multidrug resistance by targeting Bcl 2 in human gastric cancer cells. Int J Cancer. 2008, 123:372 9. 40. He L, He X, Lim LP, et al.
A microRNA component of the p53 tumor suppressor network. Nature. 2007, 447:1130 4. Kretzner et al. Page 10 Cancer Res. Author manuscript, available in PMC 2012 June 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 41. Eis PS, Tam W, Sun L, et Danoprevir 850876-88-9 al. Accumulation of miR 155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005, 102:3627 32. 42. Kluiver J, Poppema S, de Jong D, et al. BIC and miR 155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005, 207:243 9. 43. Levati L, Alvino E, Pagani E, et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA 155. Int J Oncol. 2009, 35:393 400. 44. Georgantas RW, Hildreth R, Morisot S, et al.
CD34+ hematopoietic stem progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc Natl Acad Sci USA. 2007, 104:2750 5. 45. Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE. Downregulation of c Myc is critical for valproic acid induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res. 2007, 31:1403 11. 46. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T Cell Lymphoma. Oncologist. 2007, 12:1247 52. 47. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti CD3 conditioning regimen. Proc Natl Acad Sci USA. 2008, 105:4796 801. Kretzner et al. Page 11 Cancer Res.
Author manuscript, available in PMC 2012 June 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript Figure 1. Drug toxicity. A. L540 cell growth inhibition measured by MTS assay after 72 hours treatment with vorinostat or two different aurora kinase inhibitors, MK 0457 and MK 5108. B. Apoptotic response of L540 cells at 48 and 72 hours, measured by Annexin V assay. Drug treatments from left to right: 1 DMSO = control for left half of graph, 2 Vor = 1.5 μM vorinostat for left half of graph, 3 0457 = 0.1 μM MK 0457, 4 Vor + 0457 = 1.5 μM vor + 0.1 μM MK 0457, 5 DMSO = control for right half of graph, 6 Vor = 1.5 μM vor for right half of graph, 7 5108 = 0.1 μM MK 5108, 8 Vor + 5108 = 1.5 μM vor + 0.1 μM MK 5108.
Experiments with MK 0457 were done separately from those with MK 5108 , thus average apoptotic values with DMSO and vorinostat vary within the range of their standard deviations. In all graphs, data are average of three experiments and error bars represent standard deviation. Dunnet,s t test was used to compare all treatments to the corresponding vorinostat treatment . * = p < 0.05 Kretzner et al. Page 12 Cancer Res. Author manuscript, available in PMC 2012 June 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript Figure 2. Flow cytometry data for L540 cell cycle effects of vorinostat and the AKi MK 0457 after forty eight hours of treatment, assayed for DNA content by propidium iodide. Cell cycle profiles are shown for cells treated with A. DMSO. B. 1.5 μM vorinostat. C. 0.1 μM MK 0457. D. both drugs.